Novomed completed the acquisition of Novoheart Holdings for C$100m.

Synopsis

Novomed, a company controlled by Prof. Ronald Li, CEO and a director of Novoheart, completed the acquisition of Novoheart Holdings, a global stem cell biotechnology company, for C$100m. Following closing of the transaction, Novoheart shares were de-listed from the TSXV.

Principals

target

Novoheart Holdings

bidder

NOVOMED

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (1)

ronald li

CEO at NOVOHEART HOLDINGS

Manager

target

Deal

£ 59 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy